These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Asthma Phenotypes Defined From Parameters Obtained During Recovery From a Hospital-Treated Exacerbation. Qiu R; Xie J; Chung KF; Li N; Yang Z; He M; Li J; Chen R; Zhong N; Zhang Q J Allergy Clin Immunol Pract; 2018; 6(6):1960-1967. PubMed ID: 29477568 [TBL] [Abstract][Full Text] [Related]
6. Prospective study of disease persistence and lung function trajectories of childhood asthma. Tang MF; Leung ASY; Ngai NA; Chan OM; Wong GWK; Leung TF Pediatr Allergy Immunol; 2022 Feb; 33(2):e13726. PubMed ID: 35212048 [TBL] [Abstract][Full Text] [Related]
7. Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab. Bergantini L; d'Alessandro M; Cameli P; Bianchi F; Sestini P; Bargagli E; Refini RM Int Arch Allergy Immunol; 2020; 181(10):746-753. PubMed ID: 32731216 [TBL] [Abstract][Full Text] [Related]
8. Platelet activation, P-selectin, and eosinophil β1-integrin activation in asthma. Johansson MW; Han ST; Gunderson KA; Busse WW; Jarjour NN; Mosher DF Am J Respir Crit Care Med; 2012 Mar; 185(5):498-507. PubMed ID: 22227382 [TBL] [Abstract][Full Text] [Related]
9. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. Molfino NA; Kuna P; Leff JA; Oh CK; Singh D; Chernow M; Sutton B; Yarranton G BMJ Open; 2016 Jan; 6(1):e007709. PubMed ID: 26739717 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288 [TBL] [Abstract][Full Text] [Related]
11. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Peters MC; McGrath KW; Hawkins GA; Hastie AT; Levy BD; Israel E; Phillips BR; Mauger DT; Comhair SA; Erzurum SC; Johansson MW; Jarjour NN; Coverstone AM; Castro M; Holguin F; Wenzel SE; Woodruff PG; Bleecker ER; Fahy JV; Lancet Respir Med; 2016 Jul; 4(7):574-584. PubMed ID: 27283230 [TBL] [Abstract][Full Text] [Related]
12. [Study of the clinical phenotype of symptomatic chronic airways disease by hierarchical cluster analysis and two-step cluster analyses]. Ning P; Guo YF; Sun TY; Zhang HS; Chai D; Li XM Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):679-83. PubMed ID: 27586974 [TBL] [Abstract][Full Text] [Related]
13. Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3. Gaffin JM; Petty CR; Sorkness RL; Denlinger LC; Phillips BR; Ly NP; Gaston B; Ross K; Fitzpatrick A; Bacharier LB; DeBoer MD; Teague WG; Wenzel SE; Ramratnam S; Israel E; Mauger DT; Phipatanakul W; J Allergy Clin Immunol; 2023 Jan; 151(1):138-146.e9. PubMed ID: 36041656 [TBL] [Abstract][Full Text] [Related]
14. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Cottin V; Khouatra C; Dubost R; Glérant JC; Cordier JF Allergy; 2009 Apr; 64(4):589-95. PubMed ID: 19154547 [TBL] [Abstract][Full Text] [Related]
15. The Impact of Insulin Resistance on Loss of Lung Function and Response to Treatment in Asthma. Peters MC; Schiebler ML; Cardet JC; Johansson MW; Sorkness R; DeBoer MD; Bleecker ER; Meyers DA; Castro M; Sumino K; Erzurum SC; Tattersall MC; Zein JG; Hastie AT; Moore W; Levy BD; Israel E; Phillips BR; Mauger DT; Wenzel SE; Fajt ML; Koliwad SK; Denlinger LC; Woodruff PG; Jarjour NN; Fahy JV; Am J Respir Crit Care Med; 2022 Nov; 206(9):1096-1106. PubMed ID: 35687105 [No Abstract] [Full Text] [Related]
16. A randomized, open labeled, comparative study to assess the efficacy and safety of controller medications as add on to inhaled corticosteroid and long-acting β2 agonist in the treatment of moderate-to-severe persistent asthma. Patel YA; Patel P; Bavadia H; Dave J; Tripathi CB J Postgrad Med; 2010; 56(4):270-4. PubMed ID: 20935397 [TBL] [Abstract][Full Text] [Related]
17. Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations. Matsunaga K; Hirano T; Oka A; Tanaka A; Kanai K; Kikuchi T; Hayata A; Akamatsu H; Akamatsu K; Koh Y; Nakanishi M; Minakata Y; Yamamoto N J Allergy Clin Immunol Pract; 2015; 3(5):759-64.e1. PubMed ID: 26054551 [TBL] [Abstract][Full Text] [Related]
18. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab. Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693 [TBL] [Abstract][Full Text] [Related]
19. Identification of asthma phenotypes in a tertiary care medical center. Kuhlen JL; Wahlquist AE; Nietert PJ; Bains SN Am J Med Sci; 2014 Dec; 348(6):480-5. PubMed ID: 25319436 [TBL] [Abstract][Full Text] [Related]
20. Impact of exacerbations on lung function, resource utilization, and productivity: results from an observational, prospective study in adults with uncontrolled asthma. Wisnivesky J; Federmann E; Eckert L; West E; Amand C; Kamar D; Teper A; Khan AH J Asthma; 2023 Jun; 60(6):1072-1079. PubMed ID: 36218309 [No Abstract] [Full Text] [Related] [Next] [New Search]